Alpha 2.0
Login Register
» Authors » Katharine Batt

Katharine Batt

Explore the profile of Katharine Batt including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 33
Citations 179
Followers 0
Related Specialties
Hematology
General Medicine
Health Services
Top 10 Co-Authors
David L Cooper
Michael Recht
Christine L Kempton
Joanna P MacEwan
Julia Thornton Snider
Neeraj N Iyer
Marlon Graf
Priti Pednekar
Michael Wang
Michael Bullano
Published In
Am J Manag Care
J Blood Med
Eur J Haematol
Patient Prefer Adherence
J Manag Care Spec Pharm
Affiliations
Soon will be listed here.
Recent Articles
1.
The Importance of Clinical Context and Consistency in Methodology When Using Matching-Adjusted Indirect Comparisons (MAICs) to Compare Outcomes
Batt K, Klamroth R, Mancuso M, Tiede A, Mantovani L
Int J Gen Med . 2024 Sep; 17:3927-3932. PMID: 39268177
Hemophilia A is rare, which makes large, randomized, controlled, statistically driven, head-to-head comparison trials difficult. Matching-adjusted indirect comparisons (MAICs) are validated statistical tools designed to help make the results of...
2.
Gaining Consensus Around Patient Risk Groups and Prognostic Profiles to Guide CMV Management Among Patients With Allogeneic Hematopoietic Stem Cell Transplant: Insights From a Delphi Panel With Hematopoietic Stem Cell Transplant Experts
Graf M, Tuly R, Pednekar P, Wang C, Batt K
Transplant Proc . 2024 Feb; 56(2):394-408. PMID: 38369412
Introduction: This study aimed to characterize patient risk groups and prognostic profiles to optimize clinical decision-making and guide appropriate medical cytomegalovirus (CMV) management among patients with allogeneic hematopoietic stem cell...
3.
Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis
Xing S, Batt K, Kuharic M, Bullano M, Caicedo J, Chakladar S, et al.
J Manag Care Spec Pharm . 2023 Jun; 29(6):626-634. PMID: 37276033
Hemophilia A is often viewed as a male disease; females are usually considered asymptomatic hemophilia A carriers. However, hemophilia A carriers may experience mild-to-severe bleeding events. To compare clinical characteristics,...
4.
Real-world analysis of patients with haemophilia A and haemophilia A carriers in the United States: Demographics, clinical characteristics and costs
Batt K, Xing S, Kuharic M, Bullano M, Caicedo J, Chakladar S, et al.
Haemophilia . 2023 May; 29(3):809-818. PMID: 37148500
Introduction: Females with haemophilia A (HA [FHAs]) and HA carriers (HACs) have an increased risk of bleeding and complications compared to the general population. Aim: To examine the characteristics, billed...
5.
Gaining consensus around patient risk groups and prognostic profiles to guide CMV management among patients with solid organ transplant: Insights from a Delphi panel with SOT experts
Pednekar P, Graf M, Tuly R, Batt K, Wang C
Clin Transplant . 2023 Jan; 37(8):e14905. PMID: 36603193
Introduction: This study aimed to characterize patient risk groups and respective prognostic profiles to optimize clinical decision-making and guide appropriate medical cytomegalovirus (CMV) management among patients with solid organ transplant...
6.
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A
Bullano M, Cool C, Schultz B, Durgapal S, Sacks N, Liu Y, et al.
Expert Rev Pharmacoecon Outcomes Res . 2022 Dec; 23(2):225-230. PMID: 36537696
Objective: To evaluate the financial impact of utilizing rpFVIII or rFVIIa during a hospital admission for the diagnosis of acquired hemophilia A (AHA) by reviewing the margin between the cost...
7.
Estimating Productivity Loss from Breast and Non-Small-Cell Lung Cancer among Working-Age Patients and Unpaid Caregivers: A Survey Study Using the Multiplier Method
Chiu K, MacEwan J, May S, Bognar K, Peneva D, Zhao L, et al.
MDM Policy Pract . 2022 Aug; 7(2):23814683221113846. PMID: 35936828
Highlights: Cancer can have a profound impact on productivity. This study demonstrates how the disease affects not only patients but also the informal or unpaid individuals who care for patients.An...
8.
A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab
Batt K, Schultz B, Caicedo J, Hollenbeak C, Agrawal N, Chatterjee S, et al.
Curr Med Res Opin . 2022 Jul; 38(10):1685-1693. PMID: 35880468
Objective: Factor VIII (FVIII) replacement and emicizumab have demonstrated efficacy for prevention of bleeds among patients with hemophilia A (PwHA) compared to on-demand (OD) use. Evidence investigating clinical outcomes and...
9.
Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements
Alexander W, Jensen I, Hathway J, Srivastava K, Cyr P, Sidonio Jr R, et al.
J Manag Care Spec Pharm . 2022 Mar; 28(5):518-527. PMID: 35343812
A mainstay of treatment in patients with hemophilia with inhibitors (PWIs) is the use of a recombinant factor VIIa (rFVIIa) bypassing agent. A new rFVIIa product may allow reduced rFVIIa...
10.
Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
Vashi P, Batt K, Klamroth R, Mancuso M, Majewska R, Tiede A, et al.
J Blood Med . 2021 Nov; 12:935-943. PMID: 34754257
Purpose: To assess the efficacy and FVIII consumption of BAY 94-9027 versus N8-GP in prophylaxis in adolescent and adult patients with severe hemophilia A (HA). Patients And Methods: A systematic...